Prosecution Insights
Last updated: October 02, 2026

Examiner: RAGHU, GANAPATHIRAM

Tech Center 1600 • Art Units: 1652 1653 1656 1699

This examiner grants 74% of resolved cases

Analysis

Ganapathiram Raghu serves in Tech Center 1600 and Art Unit 1652. The examiner has a total of 1313 resolved cases. The allowance rate for these cases is 73.6%. This 73.6% rate provides a metric for the likelihood of obtaining a patent grant under this examiner's review. Applicants can evaluate their prosecution strategy based on this frequency of outcomes.

The interview lift is 26.4%. This 26.4% lift suggests that engaging in a direct dialogue with the examiner is associated with an increase in the probability of allowance. The 26.4% lift indicates that an interview is a tool for advancing the case. The median days to allowance is 918. This 918 day duration represents the middle point of the time required to reach a grant, helping practitioners manage expectations regarding the length of the patent acquisition process. The 918 days serve as a benchmark for planning in Art Unit 1652.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

73.6%
Allow Rate
+13.6% vs TC avg
1,342
Total Applications
+26.4%
Interview Lift
918
Avg Prosecution Days
Based on 1313 resolved cases, 2023–2026

Rejection Statute Breakdown

8.1%
§101 Eligibility
21.2%
§102 Novelty
31.0%
§103 Obviousness
32.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18021059 MICROORGANISM FOR PRODUCING PUTRESCINE AND PROCESS FOR PRODUCING PUTRESCINE BY USING SAME Non-Final OA CJ CHEILJEDANG CORPORATION
18318424 METHODS FOR BIOFUEL AND CHEMICAL PRODUCTION Final Rejection The Regents of the University of California
18567935 METHOD FOR CLEAVING POLYURETHANE PRODUCTS Non-Final OA Covestro Deutschland AG
18003489 TREATMENT OF POST-OPERATIVE SURGICAL PAIN Final Rejection IPSEN BIOPHARM LIMITED
18849848 CHEMOENZYMATIC SYNTHESIS OF SELENONEINE AND ITS ANALOGS Non-Final OA The Trustees of Princeton University
18860038 LYTIC AGENT FOR ENTEROCOCCUS FAECALIS Non-Final OA THE UNIVERSITY OF TOKYO
18851231 METHOD FOR PRODUCING METHACRYLIC ACID Non-Final OA RIKEN
18353673 ACID TOLERANT CLOSTRIDIA Final Rejection Alliance for Energy Innovation, LLC
18852356 METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE Non-Final OA The United States Government as represented by the Department of Veterans Affairs
18921390 COLLOIDAL FIBRIN NANOPARTICLE COMPOSITIONS AND USES Non-Final OA NORTH CAROLINA STATE UNIVERSITY
18863702 GENETICALLY MODIFIED YEAST AND FERMENTATION PROCESSES FOR THE PRODUCTION OF XYLITOL Non-Final OA Cargill, Incorporated
18564150 METHODS FOR PRODUCING BETALAINS IN YEAST Final Rejection Danmarks Tekniske Universitet
18593547 POLYMERIC ENCAPSULATION OF WHOLE CELLS AS BIOREACTORS Non-Final OA Lawrence Livermore National Security, LLC
18713604 PRODUCTION OF D-LYSERGIC ACID Non-Final OA Imperial College Innovations Limited
18847362 L-THREONINE TRANSALDOLASES AND USES THEREOF Non-Final OA UNIVERSITY OF DELAWARE
18840367 PROCESS FOR PRODUCING FERMENTATION PRODUCTS AND BIOGAS FROM STARCH-CONTAINING MATERIALS Non-Final OA Novozymes A/S
18767374 METHOD FOR PRODUCING SYNGAS FERMENTATION PRODUCTS USING HIGHLY ACTIVE MICROORGANISMS Non-Final OA GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
18742139 DRUG SCREENING METHOD AND MODEL FOR MONITORING PLATINUM-RESISTANT OVARIAN CANCER TUMOR GROWTH AND METASTASES Non-Final OA THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA
18915097 PRODUCTION OF ISOPRENOIDS Non-Final OA AMYRIS, INC.
18578894 NOVEL ENZYMES FOR THE PRODUCTION OF GAMMA-AMBRYL ACETATE Final Rejection Amyris, Inc.
18724015 KNOCKOUT OF ptsP GENE ELEVATES ACTIVE GENE EXPRESSION Non-Final OA ABSCI CORPORATION
18325786 PRODUCT Non-Final OA CEMVITA FACTORY, INC.
17921372 Yeast strains for reducing contamination by lactic acid bacteria Non-Final OA Université Libre de Bruxelles

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month